Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC).

Wassim Abida,David Campbell,Akash Patnaik,Brieuc Sautois,Jeremy Shapiro,Nicholas J. Vogelzang,Alan H. Bryce,R. McDermott,Francesco Ricci,Julie Rowe,Jingsong Zhang,Andrea Loehr,Darrin Despain,Melanie Dowson,Tony Golsorkhi,Simon Chowdhury

Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC).

2020

Wassim Abida
David Campbell
Akash Patnaik
Brieuc Sautois
Jeremy Shapiro
Nicholas J. Vogelzang
Alan H. Bryce
R. McDermott
Francesco Ricci
Julie Rowe
Jingsong Zhang
Andrea Loehr
Darrin Despain
Melanie Dowson
Tony Golsorkhi
Simon Chowdhury

178Background: The phase 2 TRITON2 study (NCT02952534) is evaluating the PARP inhibitor rucaparib in pts with mCRPC and a deleterious germline or somatic alteration in BRCA (BRCA pts) or 1 of 13 ot...

Keywords:

Oncology
Rucaparib
Pathology
Prostate cancer
Castration
Internal medicine
Medicine
Somatic cell
PARP inhibitor
castration resistant
Germline
Cancer research
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations